ENTRY       D04187                      Drug
NAME        Fingolimod hydrochloride (JAN/USAN);
            Gilenya (TN)
PRODUCT     GILENYA (Novartis Pharmaceuticals Corporation)
  GENERIC   FINGOLIMOD (Apotex Corp.)
            FINGOLIMOD (Ascend Laboratories)
            FINGOLIMOD (Camber Pharmaceuticals)
            FINGOLIMOD (Dr. Reddy's Laboratories)
            FINGOLIMOD (Glenmark Pharmaceuticals)
            FINGOLIMOD (Mylan Pharmaceuticals)
            FINGOLIMOD (Rising Pharmaceuticals)
            FINGOLIMOD (Solco Healthcare US)
            FINGOLIMOD (Strides Pharma Science Limited)
            FINGOLIMOD (Sun Pharmaceutical Industries)
            FINGOLIMOD (Zydus Lifesciences Limited)
            FINGOLIMOD (Zydus Pharmaceuticals USA)
            FINGOLIMOD HYDROCHLORIDE (Accord Healthcare)
FORMULA     C19H33NO2. HCl
EXACT_MASS  343.2278
MOL_WEIGHT  343.9318
CLASS       Metabolizing enzyme substrate
             DG02980  CYP4F2 substrate
REMARK      Therapeutic category: 3999
            ATC code: L04AA27
            Chemical structure group: DG00741
            Product (DG00741): D04187<JP/US> D12549<US>
EFFICACY    Immunosuppressant, Sphingosine-1-phosphate receptor agonist
  DISEASE   Multiple sclerosis [DS:H01490]
COMMENT     Sphingosine [CPD:C00319] analog
            Prophylaxis of organ rejection in patients receiving allogenic renal transplants
TARGET      S1PR1 [HSA:1901] [KO:K04288]
  PATHWAY   hsa04071(1901)  Sphingolipid signaling pathway
            hsa04080(1901)  Neuroactive ligand-receptor interaction
METABOLISM  Enzyme: CYP4F2 [HSA:8529]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA27 Fingolimod
                  D04187  Fingolimod hydrochloride (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Central Nervous System Agents
              Multiple Sclerosis Agents
               Fingolimod
                D04187  Fingolimod hydrochloride (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D04187  Fingolimod hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG02980  CYP4F2 substrate
               DG00741  Fingolimod
                D04187  Fingolimod hydrochloride
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Sphingolipid
                S1PR1
                 D04187  Fingolimod hydrochloride (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D04187
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04187
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D04187
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D04187
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D04187
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG02980  CYP4F2 substrate
               DG00741  Fingolimod
DBLINKS     CAS: 162359-56-0
            PubChem: 47206133
            ChEBI: 63112
            LigandBox: D04187
ATOM        23
            1   C8x C    16.8213  -16.0972
            2   C8y C    16.8213  -17.5085
            3   C8x C    18.0435  -18.2142
            4   C8x C    19.2658  -17.5085
            5   C8y C    19.2658  -16.0972
            6   C8x C    18.0435  -15.3915
            7   C1b C    20.5069  -15.3804
            8   C1b C    21.7218  -16.0817
            9   C1d C    22.9137  -15.3934
            10  C1b C    24.1174  -16.0883
            11  O1a O    25.3149  -15.3967
            12  C1b C    24.1261  -14.6934
            13  O1a O    24.1261  -13.2934
            14  N1a N    21.7013  -14.6934
            15  C1b C    15.5968  -18.2157
            16  C1b C    14.3875  -17.5177
            17  C1b C    13.2072  -18.1993
            18  C1b C    12.0122  -17.5094
            19  C1b C    10.8247  -18.1951
            20  C1b C     9.6334  -17.5072
            21  C1b C     8.4441  -18.1940
            22  C1a C     7.2538  -17.5066
            23  X   Cl   24.0599  -18.6934
BOND        22
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12    9  12 1
            13   12  13 1
            14    9  14 1
            15    2  15 1
            16   15  16 1
            17   16  17 1
            18   17  18 1
            19   18  19 1
            20   19  20 1
            21   20  21 1
            22   21  22 1
///
